MSM Stock Overview
Massmedica S.A. engages in the distribution of implants and other medical materials used in the treatment of musculoskeletal system diseases and regenerative medicines in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Massmedica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł2.80 |
| 52 Week High | zł3.76 |
| 52 Week Low | zł2.20 |
| Beta | 0.061 |
| 1 Month Change | -2.78% |
| 3 Month Change | -19.54% |
| 1 Year Change | -10.83% |
| 3 Year Change | -53.33% |
| 5 Year Change | -67.02% |
| Change since IPO | -64.10% |
Recent News & Updates
Optimistic Investors Push Massmedica S.A. (WSE:MSM) Shares Up 41% But Growth Is Lacking
Mar 07
Calculating The Intrinsic Value Of Massmedica S.A. (WSE:MSM)
Jan 05Recent updates
Optimistic Investors Push Massmedica S.A. (WSE:MSM) Shares Up 41% But Growth Is Lacking
Mar 07Calculating The Intrinsic Value Of Massmedica S.A. (WSE:MSM)
Jan 05I Ran A Stock Scan For Earnings Growth And Massmedica (WSE:MSM) Passed With Ease
Sep 14Massmedica S.A.'s (WSE:MSM) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 15
Shareholder Returns
| MSM | PL Healthcare | PL Market | |
|---|---|---|---|
| 7D | 0.7% | 1.9% | -1.2% |
| 1Y | -10.8% | 41.5% | 24.4% |
Return vs Industry: MSM underperformed the Polish Healthcare industry which returned 38.9% over the past year.
Return vs Market: MSM underperformed the Polish Market which returned 24% over the past year.
Price Volatility
| MSM volatility | |
|---|---|
| MSM Average Weekly Movement | 15.7% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.6% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: MSM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MSM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Marek Mlodzianowski | www.massmedica.com |
Massmedica S.A. engages in the distribution of implants and other medical materials used in the treatment of musculoskeletal system diseases and regenerative medicines in Poland. It offers products in the field of reconstructive, regenerative, anti-aging, and aesthetic medicine. The company’s products include dietary supplements, skin care cosmetics, sun protection creams, tools for home treatments, and intra-articular injections for regeneration of the knee joints.
Massmedica S.A. Fundamentals Summary
| MSM fundamental statistics | |
|---|---|
| Market cap | zł6.76m |
| Earnings (TTM) | zł509.97k |
| Revenue (TTM) | zł26.37m |
13.3x
P/E Ratio0.3x
P/S RatioIs MSM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSM income statement (TTM) | |
|---|---|
| Revenue | zł26.37m |
| Cost of Revenue | zł16.60m |
| Gross Profit | zł9.77m |
| Other Expenses | zł9.26m |
| Earnings | zł509.97k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 37.05% |
| Net Profit Margin | 1.93% |
| Debt/Equity Ratio | 92.0% |
How did MSM perform over the long term?
See historical performance and comparison